RxDoctor Payments DataLook up a doctor →

Anette Nieves, MD

Neurology · Ocala, FLNPI 1770658957

Payments from drug & device makers

$9,781,531in general payments, 2019–2025

Across 916 payments — averaging $10,679 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3.8M
  • Genentech, Inc.$2.9M
  • Eli Lilly$1.5M
  • Eisai Inc.$641K
  • UCB SA$450K
  • AbbVie$274K
  • plus $198K from 40 others
$9,686in research payments, 2019–2025

Across 4 payments — averaging $2421.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$10K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen15$3,823,630
Genentech, Inc.215$2,942,762
Eli Lilly40$1,451,161
Eisai Inc.94$641,136
UCB SA2$450,241
AbbVie(2 entities)174$274,391
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)26$62,564
Janssen Research & Development, LLC15$40,492
Merck9$39,731
Amgen4$24,792
E.r. Squibb & Sons, L.L.C.2$20,268
Ipsen Innovation2$3,485
F. Hoffmann-la Roche AG2$1,200
Teva Pharmaceuticals USA, Inc.78$948
Acadia Pharmaceuticals Inc47$772
Neurocrine Biosciences, Inc.30$586
MDD US Operations, LLC25$429
Amneal Pharmaceuticals LLC21$390
Otsuka America Pharmaceutical, Inc.15$313
Boston Scientific10$306
Novartis1$272
Lundbeck LLC11$232
Kyowa Kirin, Inc.8$178
Supernus Pharmaceuticals, Inc.14$170
GE HealthCare5$122
Merz Pharmaceuticals, LLC5$116
Argenx US, Inc.5$100
Corium, LLC3$97
Avion Pharmaceuticals4$64
Lilly USA, LLC3$62
Idorsia Pharmaceuticals US Inc4$61
UCB, Inc.4$61
Axsome Therapeutics, Inc.3$54
C2n Diagnostics, LLC3$54
Arbor Pharmaceuticals, Inc.3$38
Adamas Pharmaceuticals, Inc.3$37
Medtronic1$36
Cala Health, Inc.2$36
Life Molecular Imaging Ltd1$26
Abbott1$24
Sunovion Pharmaceuticals Inc.1$18
Revance Therapeutics, Inc.1$17
Endo Pharmaceuticals Inc.1$15
Acorda Therapeutics, Inc1$15
Insightec,inc1$14
Vertical Pharmaceuticals, LLC1$12

How this compares

$9,781,531 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$446,735
Medicare patients
867
Services billed
16,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Ocala

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →